Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT03949283IIIPlatinum resistant ovarian cancerStandard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian CancerCA, FL, IN, LA, OH, OK, PA, WVView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
DocetaxelTaxotereMicrotubule stabilizer/mitotic inhibitorApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT04729387IIIPlatinum resistant or refractory gBRCA WT high grade serous or endometrioid ovarian cancerEPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian CancerAZ, AR, FL, IL, MD, MA, NY, OH, SD, TN, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AlpelisibPI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, PiqrayPI3K alpha inhibitorApproved in Other Cancers
OlaparibLynparza, AZD2281PARP inhibitorApproved in Ovarian Cancer
NCT04209855IIIPlatinum resistant FRalpha+ high grade serous ovarian cancerMIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionAL, AK, AZ, CA, CO, CT, FL, GA, HI, IL, IN, KS, KY, LA, MD, MA, MI, MN, MO, MT, NV, NJ, NY, NC, OH, OK, OR, PA, RI, TN, TX, VA, WA, WVView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
NCT05043402IIIPlatinum resistant ovarian cancer that must have had prior bevacizumabAn Open Label Randomized Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerContact research study staffView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NavicixizumabOMP-305B83, anti-DLL4/VEGF bispecific monoclonal antibody OMP-305B83DLL4 and VEGF antagonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04729608IIIPlatinum resistant high grade serous ovarian cancer; no prior paclitaxel for platinum resistant diseaseA Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)AL, CA, CO, CT, FL, GA, IL, IN, KY, LA, ME, MD, MA, MI, MN, MO, MT, NV, NJ, NM, NY, NC, OH, OK, OR, PA, RI, SC, SD, TN, TX, VA, WA, WV, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Batiraxceptanti-AXL fusion protein AVB-S6-500, AVB-S6-500, AVB-500GAS6 antagonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT05116189IIIPlatinum resistant ovarian cancer; 1-2 prior systemic therapiesA Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)CA, FL, GA, IN, MD, MA, NJ, NC, OH, OR, PA, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT05281471IIIPlatinum resistant or refractory ovarian cancer that must have had prior bevacizumabA Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian CancerFLView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
Olvimulogene nanivacirepveclight-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1Induces immune response and tumor cell lysisClinical Trials
NCT05257408IIIPlatinum resistant high grade serous or high grade endometrioid ovarian cancerA Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Investigator's Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerContact research study staffView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
RelacorilantRELA, CORT125134GR antagonistClinical Trials
NCT05092360IIIPlatinum resistant or refractory ovarian cancer that must have had prior bevacizumab (≤5 prior therapies for platinum resistant disease)A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerFL, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Nemvaleukin alfaintermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230IL-2/IL-15R beta and gamma agonistClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04172597IIAdvanced solid tumors with EGFR or ERBB2 activating mutationsA Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced MalignanciesCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PoziotinibNOV120101, pan-HER kinase inhibitor HM781-36BEGFR, HER2, HER4 kinase inhibitor
NCT02843165IIAdvanced solid tumors with lesion treatable with radiation therapyRandomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic DiseaseCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyIrradiation, Radiotherapy
NCT02364713IIPlatinum resistant, refractory or persistent ovarian cancer (no measurable disease outside the peritoneal cavity)MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal CancerAZ, FL, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MV-NISoncolytic measles virus encoding thyroidal sodium iodide symporterInduces immune response and tumor cell lysisClinical Trials
NCT03907475IIAdvanced solid tumors (with tumor amenable to skin biopsy)DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid TumorsMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CapecitabineXeloda, CAPERNA processing and thymidylate synthase inhibitorNCCN Guidelines for Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
nab-PaclitaxelPaclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007Microtubule stabilizer/mitotic inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT02834013IIAdvanced ovarian small cell cancerDART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsAL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT04482309IIAdvanced HER2+ solid tumorsA Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)CA, IL, IN, MA, NJ, NY, NC, TN, TX, VA, WAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab deruxtecanT-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201aADC: anti-HER2 + topoisomerase I inhibitor (Dxd)Approved in Other Cancers
NCT03732950IIRecurrent ovarian cancerA Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression ProfilingCA, MNView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03113487IIPlatinum resistant or refractory ovarian cancerP53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerCAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
p53MVAModified Vaccinia Virus Ankara Vaccine Expressing p53, MVAp53Immune response against p53 tumor antigenClinical Trials
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03911557IIAdvanced solid tumors with moderate/high TMBPhase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid TumorsKYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT04056910IIAdvanced solid tumors with IDH1 mutationsPhase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid TumorsPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IvosidenibAG-120IDH1 inhibitorApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03935893IIAdvanced solid tumorsA Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid CancersPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AldesleukinIL-2 receptor agonistApproved in Other Cancers
Autologous TILsImmune response against tumor-associated antigensClinical Trials
CyclophosphamideSendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, CiclofosfamidaDNA damaging agentApproved in Ovarian Cancer
FludarabineFludara Oral, 2-F-ara-AMP, BeneflurDNA synthesis inhibitorApproved in Other Cancers
NCT02568267IIAdvanced solid tumors with NTRK1/2/3, ROS1, or ALK rearrangementsAn Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene RearrangementsTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EntrectinibRXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, RozlytrekALK, TRK, ROS1 kinase inhibitorApproved in Other Cancers
NCT01851369IIGranulosa cell ovarian cancerA Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and LymphomasMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
MethoxyamineTRC102Base excision repair inhibitorClinical Trials
TemozolomideTemodal, Temodar, MethazolastoneDNA damaging agentApproved in Other Cancers
NCT04171219IIAdvanced solid tumorsA Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid CancersTXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
TalabostatBXCL701, Val-boro-Pro, talabostat mesylate, PT100Dipeptidyl peptidase inhibitorClinical Trials
NCT04753216IIPlatinum resistant or refractory ovarian cancerA Phase II Trial of Irinotecan Liposome and Bevacizumab in Women With Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerILView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
BevacizumabAvastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chainVEGF antagonistApproved in Ovarian Cancer
Liposomal irinotecanOnivyde, MM-398, liposome-encapsulated irinotecan hydrochloride PEP02, nal-IRI, nanoliposomal irinotecanTopoisomerase I inhibitor
NCT04739618IIAdvanced solid tumors - intratumoral injectionA Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid CancerAZView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
ThermotherapyClinical Trials
NCT04639219IIAdvanced solid tumors with ERBB2 MUTA Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor HistologyCA, IL, IN, MA, NJ, NY, TX, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Trastuzumab deruxtecanT-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201aADC: anti-HER2 + topoisomerase I inhibitor (Dxd)Approved in Other Cancers
NCT02312245IIRecurrent ovarian cancerAvatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube CancersAZ, FL, MNView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT03693014IIAdvanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatmentA Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint BlockadeCT, NJ, NY, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AtezolizumabTecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446Blocks PD-L1 inhibition of T cellsApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
Radiation TherapyIrradiation, Radiotherapy
NCT04770246IIAdvanced solid tumorsA Phase 2 Study of TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsCA, NY, OH, PA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TAS-117Akt inhibitorClinical Trials
NCT04771520IIAdvanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I)Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsTXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvapritinibPDGFRa and c-Kit inhibitorApproved in Other Cancers
NCT04233567IIAdvanced solid tumors with FGFR alterationsA Phase II Study of Oral Infigratinib in Adult Patients With Advanced or Metastatic Solid Tumors With FGFR1-3 Gene Fusions or Other FGFR Genetic AlterationsOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
InfigratinibBGJ398, pan FGFR Kinase Inhibitor BGJ398pan-FGFR kinase inhibitorApproved in Other Cancers
NCT04876456IIRecurrent Germ Cell TumorsA Phase II Trial Evaluating the Efficacy of Cabozantinib in the Treatment of Incurable Patients With Refractory Germ Cell TumorsINView Drugs